News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management


11 December 2008 CSL Behring Launches Voice2Voice™ Vivaglobin® Advocacy Program for New Patients and Caregivers

CSL Behring, a worldwide leader in developing immunoglobulin therapies, announced today the launch of Voice2Voice™, a consumer outreach program offering peer-to-peer support to primary immunodeficiency (PI) patients and caregivers. The program will offer assistance exclusively to new patients as they begin at-home use of Vivaglobin® (Immune Globulin Subcutaneous, Human), the first and only U.S. Food and Drug Administration-approved subcutaneous immunoglobulin (Ig) for treatment of patients with primary immunodeficiency.

> Read More
25 September 2008 Data Published in Journal of Clinical Immunology Show Privigen™ Demonstrates Effectiveness and Tolerability in Patients with Primary Immunodeficiencies

New L-Proline Stabilized Immune Globulin Intravenous (Human) 10 Percent Liquid can be stored at room temperature, offering convenience to healthcare professionals

> Read More
17 March 2008 Study Shows Privigen™10% Liquid Immunoglobulin Preparation for Intravenous Use, Is an Effective Replacement Therapy in Patients with Primary Immune Deficiencies

CSL Behring presented data today on the pharmacokinetic properties of its new immune globulin intravenous (human) 10% product, Privigen™. Researchers found that Privigen leads to immunoglobulin G (IgG) pharmacokinetic characteristics and specific antibody levels equivalent to those described for other intravenous immunoglobulin (IVIg) preparations. The study was presented at the American Academy of Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, U.S.

> Read More
17 March 2008 L-Proline Stabilized Immune Globulin Intravenous (Human) 10% Liquid, Privigen™, Demonstrates Good Tolerability at High Infusion Rates

CSL Behring announced data today from a study that demonstrates its new liquid immune globulin intravenous (human) 10% product (Privigen™), is well-tolerated in patients with Primary Immune Deficiencies (PI); a group of predominantly genetic disorders that cause a malfunction in part or all of the immune system. New data from an additional study also showed that Privigen is well-tolerated when administered at high infusion rates. Both studies were presented at the American Academy of Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, U.S.

> Read More
09 November 2007 New Hope in Immunodeficiency Treatment for Improved Tolerability and Convenience in the use of Immune Globulin Intravenous (Human) 10% Liquid (Privigen®)

CSL Behring today announced data on the use of L-proline as a new single stabilizer for Immune Globulin Intravenous (Human) 10% Liquid (Privigenâ). Researchers found that the use of L-proline, a naturally occurring amino-acid, inhibited dimer formation more efficiently when compared with other additives like glycine, used as a stabilizer in conventional immunoglobulin products. In addition, the formulation with L-proline was found to prevent aggregation. The data were presented today at the American Congress of Allergy, Asthma and Immunology (ACAAI) in Dallas, Texas.

> Read More
Page 10 of 10 First | Previous

LinkedIn Twitter Facebook Google+